Clinical characteristics of patients described in the World Health Organization database of individual case safety reports, performed at the Uppsala Drug Monitoring Centre until 16 March, 2021 for the three vaccines: Comirnaty from Pfizer–BioNtech, the Moderna COVID-19 vaccine and the Oxford–AstraZeneca vaccine (AZD1222)
| Comirnaty | Moderna | AZD1222 | |
| Total cases | 1197 | 325 | 639 |
| Age years | 76 (18–102) | 72 (19–102) | 67 (19–99) |
| Patient sex | |||
| Female | 708 (59.1%) | 173 (53.2%) | 332(52%) |
| Male | 483 (40.4%) | 152 (46.8%) | 291 (45.5%) |
| Unknown | 6 (0.5%) | 16 (2.5%) | |
| Death | 223 (18.6%) | 53 (16.3%) | 82 (12.8%) |
| Global time in days to thrombotic event | 3 (0–52) | 2 (0–63) | 5 (0–55) |
| Venous thrombotic events | 381 (31.8%) | 80 (24.6%) | 334 (52.3%) |
| Age years | 62 (21–98) | 58.5 (19–96) | 63 (18 - 99) |
| Time in days to thrombotic event | 4 (0–50) | 4 (0-39) | 6 (0–55) |
| Pulmonary embolism | 211 (17.6%) | 53 (16.3%) | 115 (18%) |
| Lower limb thrombosis | 111 (9.3%) | 13 (4%) | 113 (17.7%) |
| Cerebral venous sinus thrombosis | 3 (0.3%) | 3 (0.9%) | 6 (0.9%) |
| Cerebral venous thrombosis | 1 (0.1%) | 1 (0.2%) | |
| Undetermined venous thrombotic event | 42 (3.5.%) | 10 (3.1%) | 92 (14.4%) |
| Others | 13 (1.1%) | 1 (0.3%) | 7 (1.1%) |
| Arterial thrombotic events | 813 (67.9%) | 253 (77.6%) | 308 (48.2%) |
| Age years | 80 (18–102) | 75 (21–102) | 70 (21–99) |
| Time in days to thrombotic event | 2 (0–52) | 2 (0–63) | 2 (0–38) |
| Stroke | 561 (46.9%) | 173 (53.1%) | 219 (34.3%) |
| Acute myocardial infarction | 238 (19.9%) | 67 (20.6%) | 81 (12.7%) |
| Stroke and myocardial infarction | 2 (0.2%) | 3 (0.9%) | |
| Others | 12 (1%)# | 10 (3.1%) | 8 (1.3%)¶ |
| Concomitant arterial and venous thrombotic events | 10 (0.8%) | 8 (2.4%) | 4 (0.6%) |
| Age years | 70.5 (25–86) | 56 (37–94) | 57.5 (31–71) |
| Time in days to thrombotic event | 3.5 (0–11) | 2 (0–22) | 3 (1–12) |
| Acute myocardial infarction and pulmonary embolism | 4 (0.3%) | 1 (0.15%) | |
| Stroke and pulmonary embolism | 3 (0.3%) | 6 (1.85%) | 1 (0.15%) |
| Stroke and lower limb ischaemia | 1 (0.1%) | ||
| Arterio-venous fistula thrombosis | 1 (0.1%) | ||
| Arterial limb ischaemia and lower limb thrombosis | 1 (0.1%) | ||
| Stroke and lower limb thrombosis | 1 (0.31%) | ||
| Arterial and venous thrombosis | 1 (0.31%) | ||
| Pulmonary embolism and multiple thrombosis | 1 (0.15%) | ||
| Acute myocardial infarction and venous thrombosis | 1 (0.15%) | ||
| Associated thrombocytopenia and/or immunothrombosis disorders | 32 (2.6%) | 8 (2.4%) | 14 (2.2%) |
| Age years | 56 (19–92) | 64 (51–77) | 46.5 (19–73) |
| Time in days to event | 4.5 (0–25) | 4 (0–10) | 8 (2–14) |
| Thrombocytopenia associated with pulmonary embolism | 2 (0.2%) | 1 (0.3%) | 3 (0.5%) |
| Thrombocytopenia associated with acute myocardial infarction | 3 (0.3%) | ||
| Thrombocytopenia associated with stroke | 13 (1.1%) | 1 (0.2%) | |
| Thrombocytopenia linked to purpura thrombotic thrombocytopenia | 7 (0.6%) | ||
| DIC | 2 (0.2%) | ||
| DIC positive lupus anticoagulant associated with visceral venous thrombosis | 1 (0.1%) | ||
| Positive lupus anticoagulant without thrombosis | 2 (0.2%) | ||
| Positive lupus anticoagulant associated with pulmonary embolism | 2 (0.2%) | 1 (0.3%) | |
| Positive lupus anticoagulant associated with stroke | 4 (1.2%) | ||
| Positive lupus anticoagulant associated with myocardial infarction | 2 (0.6%) | ||
| Thrombocytopenia associated with splenic venous thrombosis | 1 (0.2%) | ||
| Thrombocytopenia with HIT-like mAb positive and multiple thrombosis | 1 (0.2%) | ||
| Thrombocytopenia associated with cerebral venous sinus thrombosis | 4 (0.6%) | ||
| Thrombocytopenia associated with cerebral venous thrombosis | 1 (0.2%) | ||
| DIC and pulmonary embolism | 1 (0.2%) | ||
| DIC and stroke | 2 (0.3%) |
Data are presented as n (percentage of cases reported) or median (range).#: others (limb, intestinal);¶: others (retinal, intestinal). DIC: disseminated intravascular coagulation; HIT: heparin-induced thrombocytopenia; mAb: antibody.